Inclusion Criteria:  Female patients aged from 18 to 45 years old; Clinical/trichological evidence of telogen effluvium, assessed using the Telogen Index. 3. Participants will be eligible if they have a rate strand of hair ≥ 20% of the total quantified by Thrichoscan measurement in the central-parietal region; Complaint of hair loss for at least 3 months prior to screening; Agreement to obey the procedures and requirements of the protocol and to attend the Research Institution on the day (s) and time (s) determined for the evaluations; Signature of the Informed Consent Form; SAW. Agreement to use an acceptable non-hormonal contraceptive method throughout the period of treatment and up to 60 days after the end of the study; Serum creatinine within the normal range; Relationship between AST / ALT transaminases ≤ 2.5x the upper limit of normal  Exclusion Criteria:  Pregnancy or pregnancy risk; Lactation; Childbirth occurred in the last 12 months; Patient who has undergone surgical procedures or has suffered trauma in the last 6 months; History of bleeding events in the last 6 months, SAW. Clinical evidence of female androgenic alopecia or alopecia areata; Patients with signs of menopause: menstrual irregularities or cycle failure, signs of climacteric; Laboratory evidence of thyroid diseases (variation in TSH and / or free T4 values outside normal limits); Clinical evidence of ovarian or adrenal endocrine disorders (polycystic ovaries, hirsutism, menstrual irregularities); History or presence of systemic autoimmune disease; Start or end of hormone therapy within 6 months before randomization; Deficiency diseases; Introduction, change or interruption of a hormonal contraceptive method in the last 6 months before randomization; Introduction of a restrictive diet in the last 03 months before randomization; Use of any continuous medication; Diabetes, chronic consuming disease, malabsorptive syndrome or diseases of the gastrointestinal tract; Infectious or chronic fever; Psychiatric/psychological illnesses, such as depression, anxiety or obsessive disorders; Clinical and / or laboratory evidence of anemia or ferropenia; (Hb <12 g / dL and Ferritin <40 g / L); Hair treatment to control hair loss (including shampoo, conditioner, lotions); Hair growth agent treatment within 3 months before randomization; Concomitant use of drugs that cause hair loss; Patient with a history of allergic reaction or hypersensitivity to any formulation ingredients; Other conditions considered by the evaluating physician to be reasonable for disqualifying the participation in the study.